Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the period ending September 9, 2026. The report details the announcement of Week 52 data from the open-label sentinel cohort of the reACHin Trial, a pivotal Phase 2 study evaluating once-weekly TransCon CNP (navepegritide) in infants aged 0 to <2 years with achondroplasia. The data were presented at the ESPE 2026 annual meeting.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and forward-looking statements regarding product development.
Material Changes and Clinical Highlights
The primary material update is the positive Week 52 data from the reACHin Trial sentinel cohort involving seven infants (mean age 11.7 months). Key clinical outcomes include:
- Cranio-cervical Junction Health: The Achondroplasia Foramen Magnum Score (AFMS) was stable or improved in all children. The mean change in sagittal diameter of the foramen magnum was +3.15 mm. No decompression surgeries occurred during the 52-week period.
- Linear Growth: Treatment resulted in a mean change from baseline in ACH-specific supine length Z-score of +0.42. The mean annualized growth velocity (AGV) was 9.9 cm/year.
- Pharmacokinetics: PK profiles were comparable to those observed in older children, supporting the 100 µg/kg/week dose.
- Safety and Tolerability: The drug was generally well tolerated. There were no injection site reactions, deaths, fractures, bone-related safety events, or symptomatic hypotension. No adverse events were assessed as treatment-related, and no events led to discontinuation.
Outlook, Risks, and Management Commentary
Management highlights the potential for TransCon CNP to address foramen magnum stenosis and support linear growth in infants. The filing includes extensive forward-looking statements cautioning that actual results may differ materially from projections. Key risks identified include:
- Regulatory review delays or failure to obtain approval in the US, EU, or other jurisdictions.
- Clinical development risks, including the possibility that future trials may not confirm earlier data.
- Manufacturing, supply chain, and quality issues.
- Market acceptance, pricing, and reimbursement challenges.
- Dependence on third-party manufacturers and service providers.
- Geopolitical events, currency fluctuations, and cybersecurity risks.
Investor Verification Checklist
- Verify the full enrollment status and design of the double-blinded portion of the reACHin Trial.
- Confirm the regulatory timeline for potential approval of TransCon CNP for the infant population.
- Review the Company's most recent Form 20-F for detailed financial position and cash runway.
- Monitor upcoming data readouts from the double-blinded phase of the trial.
- Assess the competitive landscape for achondroplasia treatments in the infant demographic.